ArticleFrontiers in oncology2026
Study of ß-catenin signaling pathway modulated by PTHrP in cell and animal colorectal cancer models.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a complex disease and a major cause of cancer-related deaths worldwide. One of the main obstacles in treating advanced CRC is chemotherapy resistance. In previous studies, we demonstrated that parathyroid hormone-related peptide (PTHrP) acts as a pro-tumor cytokine in CRC-derived cells, capable of modulating several mitogenic pathways and inducing β-catenin nuclear localization. Furthermore, we observed that PTHrP favors the communication between tumor cells and their microenvironment, promoting a more aggressive tumor phenotype. Using different CRC models, the first goal of this work was to further explore, how PTHrP is able to modulate the complex β-catenin signaling pathway, whereas the second aim was to examine whether this modulation by PTHrP is associated with resistance to chemotherapy agents commonly used in CRC treatment, particularly platinum-based compounds. The findings obtained
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.